Image (2d955155 686d 40cd 898e Df7d760247a5 740 1)
Lamotrigine
Product Images NDC 68071-2729
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Lamotrigine (NDC 68071-2729). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Image (2d955155 686d 40cd 898e Df7d760247a5 789 2)
Lamotrigine tablets in various strengths and shapes: 25 mg white rectangular tablets imprinted with 'U 111', 100 mg white triangular tablets imprinted with 'U 112', 150 mg white triangular tablets imprinted with 'U 113', and 200 mg light blue triangular tablets imprinted with 'U 114'.*
Image (2d955155 686d 40cd 898e Df7d760247a5 789 3)
Pdp (68071 2729 6)
Label for Lamotrigine 150 mg tablets by NuCare Pharmaceuticals, Inc. The label states quantity of 60 tablets, Rx only, and mentions trigonal shaped white biconvex tablets debossed with 'U' on one side of the break line and '113' on the other. Manufactured by Unichem Laboratories Ltd., India, packaged by NuCare Pharmaceuticals, Orange, CA. Label includes various barcodes, lot number, expiration date placeholders, and a warning to keep out of reach of children.*
Molecular Structure (Ad7af627 Ea4b 4a78 A71e Db1255416d1e 01)
Chemical structure diagram of lamotrigine showing two chlorine atoms on a benzene ring, an amino group, and a triazine ring with an amino substitution, consistent with the molecular structure of the active ingredient lamotrigine.*
Figure 1 (Ad7af627 Ea4b 4a78 A71e Db1255416d1e 02)
This is a Kaplan-Meier failure probability curve comparing Lamotrigine and Placebo over a period of approximately 100 weeks. The y-axis represents failure probability in percentage, and the x-axis represents time in weeks. Censored data points are indicated on the graph.*
Figure 2 (Ad7af627 Ea4b 4a78 A71e Db1255416d1e 03)
A Kaplan-Meier failure probability plot showing the percentage of failure over weeks for two groups: Placebo and Lamotrigine. The y-axis represents failure probability in percentage, and the x-axis represents weeks. The graph includes censoring marks indicating data points where subjects were censored during the study.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
